A phase 1 clinical trial (NCT03886831) with PRT343 (a potent, selective, oral PRMT5 inhibitor) that included MCL and other malignancies with no available treatment options has completed accrual and awaiting read out. This evidence concerns the gene PRMT5 and mantle cell lymphoma.